Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0PN8D
|
||||
| Former ID |
DNC004503
|
||||
| Drug Name |
1-(7-Methoxy-naphthalen-2-yl)-piperazine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H18N2O
|
||||
| Canonical SMILES |
COC1=CC2=C(C=CC(=C2)N3CCNCC3)C=C1
|
||||
| InChI |
1S/C15H18N2O/c1-18-15-5-3-12-2-4-14(10-13(12)11-15)17-8-6-16-7-9-17/h2-5,10-11,16H,6-9H2,1H3
|
||||
| InChIKey |
FRTFBUOBLXTGSL-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Inhibitor | [1] | |
| 5-hydroxytryptamine 1D receptor | Target Info | Inhibitor | [1] | ||
| 5-hydroxytryptamine 1B receptor | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04024:cAMP signaling pathway | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 1997 Nov 21;40(24):3974-8.5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.